Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Renal Cell Carcinoma

 

AGS-003 for Advanced Renal Cell Carcinoma
An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Investigator: Scott S. Tykodi, MD;   Conditions: Renal Cell Carcinoma;    Status: Recruiting;   Study ID: NCT01582672